**Core Concept**
The question is testing the student's knowledge of calcium channel sensitizer drugs used in the treatment of Congestive Heart Failure (CHF). Calcium channel sensitizers increase the sensitivity of the cardiac myofilaments to calcium, leading to improved contractility and enhanced cardiac output.

**Why the Correct Answer is Right**
The correct answer is a calcium channel sensitizer that works by inhibiting phosphodiesterase 3 (PDE3), which leads to an increase in cyclic AMP (cAMP) levels. This increase in cAMP sensitizes the cardiac myofilaments to calcium, allowing for improved contractility and enhanced cardiac output. This mechanism is beneficial in patients with CHF, where the heart's contractility is impaired.

**Why Each Wrong Option is Incorrect**
**Option A:** This is incorrect because it is not a calcium channel sensitizer. Instead, it is a beta-blocker, which decreases heart rate and contractility, making it contraindicated in CHF.
**Option B:** This is incorrect because it is a direct vasodilator, which can lead to reflex tachycardia and worsen CHF.
**Option C:** This is incorrect because it is an alpha-blocker, which can also lead to reflex tachycardia and worsen CHF.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that calcium channel sensitizers are beneficial in CHF due to their ability to increase contractility without increasing oxygen demand. This makes them a valuable adjunct to other treatments in CHF management.

**Correct Answer: C. Levosimendan**